GlaxoSmithKline PLC Investor Science Event: ASN Kidney Week Transcript
Thank you very much, and good afternoon, and good evening, and welcome to GSK's Investor Science Event Getting Ahead of Anemia from Chronic Kidney Disease for investors and analysts from the American Society of Nephrology Kidney Week 2021. I'm Mick Readey, your moderator for today's call and a member of the GSK IR Team.
We're here today for an update on daprodustat, a potential best-in-class new medicines for the treatment of anemia of chronic kidney disease. As usual, the presentation materials are available on gsk.com and were sent to our distribution list earlier today. Please also note that the data presented on today's call are available on the ASN website or in the accompanying publication on the New England Journal of Medicine.
Before we get started, I would like to thank Frannie DeFranco from the IR team for her contribution to today's call. Please turn to Slide 2.
Now a quick reminder of the usual safe harbor statement and forward-looking statements disclaimer. Please turn to Slide 3.
We are joined on today's call by Dr. Hal Barron, Chief Scientific
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |